Dynamic Immunomodulation by Hydrogen Capsule Therapy in SLE-associated Pulmonary Arterial Hypertension: A Case Report.
Chin Liu, Jeng-Wei Lu, Chun-Hsien Wu, Yi-Jung Ho, Shan-Wen Lui, Ting-Yu Hsieh, Kuang-Yih Wang, Feng-Cheng Liu · In vivo (Athens, Greece) · 2025
Research-use notice
Independent study record
Each H2HUBB study page organizes source-linked research details for educational use. Interpretation should remain proportional to the study design, population, controls, and limitations.
H2HUBB TAKEAWAY
In Molecular hydrogen therapy, a selective antioxidant and anti-inflammatory agent, has the capacity to modulate immune responses in these autoimmune disease patients, this case report details the clinical improvement in an SLE patient with PAH after starting adjunctive hydrogen capsule therapy, highlighting its potential as a novel approach for this challenging complication. These findings add human evidence supporting molecular hydrogen's therapeutic potential to influence blood-pressure regulation.
What the Findings Mean
H2HUBB reviewed how molecular hydrogen affected the outcomes measured in Molecular hydrogen therapy, a selective antioxidant and anti-inflammatory agent, has the capacity to modulate immune responses in these autoimmune disease patients. This case report details the clinical improvement in an SLE patient with PAH after starting adjunctive hydrogen capsule therapy, highlighting its potential as a novel approach for this challenging complication.
What the Researchers Studied
The researchers studied Molecular hydrogen therapy, a selective antioxidant and anti-inflammatory agent, has the capacity to modulate immune responses in these autoimmune disease patients.
What Effects Did Molecular Hydrogen Have?
This case report details the clinical improvement in an SLE patient with PAH after starting adjunctive hydrogen capsule therapy, highlighting its potential as a novel approach for this challenging complication. The authors concluded that a biphasic immunomodulatory effect of hydrogen therapy, that is, initially dampening immune activation, followed by a regulatory rebound after hydrogen therapy. Its low status may be result from the hydrogen-mediated suppression, while the subsequent increase potentially reflects an immune rebound following withdrawal of the immunomodulatory effects of hydrogen.
Why These Findings Matter
These findings add human evidence supporting molecular hydrogen's therapeutic potential to influence blood-pressure regulation and contribute to the growing body of molecular-hydrogen research.
How Strong Is This Evidence?
This is human clinical evidence from a case report. H2HUBB interprets the findings in the context of the study design, sample, comparator, and measured outcomes rather than using one publication as a verdict on hydrogen therapy.
Technical Study Details
H2HUBB classifies this publication as case report with human clinical evidence. The research population or model was Molecular hydrogen therapy, a selective antioxidant and anti-inflammatory agent, has the capacity to modulate immune responses in these autoimmune disease patients.
Limitations and Safety
No separate limitations or safety findings were identified in the current-study source text available to H2HUBB.
Original Study and H2HUBB Research Context
H2HUBB presents this source-grounded research record as one contribution to the broader molecular-hydrogen evidence base.